Shanghai, China

Liwei Song

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Liwei Song

Introduction

Liwei Song is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work has the potential to impact various medical applications, showcasing his innovative spirit and dedication to advancing science.

Latest Patents

Liwei Song holds a patent for "Anti-CD79b antibodies, drug conjugates, and applications thereof." This patent discloses an anti-CD79b antibody or an antigen-binding fragment thereof, along with a drug conjugate and its uses. The specific components of the antibody include HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, each comprising unique amino acid sequences that contribute to its functionality. This patent highlights his expertise in antibody engineering and therapeutic development. He has 1 patent to his name.

Career Highlights

Liwei Song is currently associated with Newbio Therapeutics, Inc., where he continues to work on innovative solutions in the biotechnology sector. His role at the company allows him to collaborate with other talented professionals in the field, further enhancing his contributions to medical science.

Collaborations

Some of his notable coworkers include Nianhe Han and Deqiang An. Their collaborative efforts contribute to the advancement of research and development in their respective areas of expertise.

Conclusion

Liwei Song's work exemplifies the spirit of innovation in biotechnology. His patent on anti-CD79b antibodies demonstrates his commitment to developing new therapeutic options. As he continues to work with Newbio Therapeutics, Inc., his contributions will likely lead to further advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…